DaVita Inc.

NYSE:DVA

Medical - Care Facilities

Healthcare
$161.79 +0.77%

+$1.60 today

Market cap
$10.18B
Beta
0.91
P/E (TTM)
18.2
EPS (TTM)
$11.60
52W Low $101.00High $213.44

Volume 1.12M

Average 0.84M

DVA Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

DaVita Inc.NYSE: DVA

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows in line with its trailing trend

Q2 FY2026 revenue of $3.55B rose 5.2% year over year, behind the +6.4% change in trailing-twelve-month revenue. Sequentially, it rose 4.1% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 5 analysts of $14.19B (+4.0%) for the fiscal year ending Dec 2026, a slowdown from the +6.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.55B+4.1% QoQ
Last fiscal yearDec 2025
$13.64B+6.5% YoY
LTMJun 2026
$14.01B+6.4% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.2%+2.8%-2.3 pp
1 year+6.5%+4.0%-2.4 pp
3-year CAGR+5.5%+3.7%-1.8 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
13.64B USD
Year-over-year change
+6.5%
4-year CAGR
+4.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How DVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +6.4% is the highest of 3, against a peer median of +2.4%.
  • Over three fiscal years its annual growth of +5.5% compares with a peer median of +2.1%.
DVA Competitors
Revenue for DVA and competitors
Company Period LTM YoY 3-year CAGR
FMSFresenius Medical Care AG & Co. KGaALTM Jun 2026€19.43B EUR-0.5%+0.4%
DVADaVita Inc.LTM Jun 2026$14.01B USD+6.4%+5.5%
BAXBaxter International Inc.LTM Jun 2026$11.47B USD+5.4%+3.8%
Peer median (excluding DVA) —+2.4%+2.1%

Competitors are the stored peer set for DVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue11.62B11.61B12.14B12.82B13.64B
Cost of Revenue7.97B8.21B8.32B8.6B9.96B
Gross Profit3.65B3.4B3.82B4.22B3.68B
Gross Margin31.4%29.3%31.5%32.9%27.0%
Research & Development00000
Selling, General & Admin1.2B1.36B1.47B1.54B1.67B
Operating Expenses1.85B2.06B2.22B2.13B1.67B
Depreciation & Amortization680.62M732.6M745.44M723.86M715.35M
EBITDA2.48B2.06B2.32B2.72B2.64B
EBITDA Margin21.4%17.7%19.1%21.3%19.4%
Operating Income1.8B1.34B1.6B2.09B2.01B
Operating Margin15.5%11.5%13.2%16.3%14.7%
Interest Income00000
Interest Expense285.25M357.02M398.55M470.47M549.67M
Other Income / Expenses(278.88M)(372.78M)(425.69M)(560.09M)(663.79M)
Income Before Tax1.52B966.28M1.18B1.53B1.35B
Pre-Tax Margin13.1%8.3%9.7%11.9%9.9%
Income Tax Expense306.73M198.09M220.12M279.66M293.11M
Net Income978.45M560.4M691.54M936.34M746.8M
Net Margin8.4%4.8%5.7%7.3%5.5%
EPS (Basic)9.305.887.6211.029.72
EPS (Diluted)8.905.717.4210.739.51
Weighted Avg Shares105.23M92.99M90.79M84.99M86.1M
Weighted Avg Shares (Diluted)109.95M95.83M93.18M87.27M88.1M

DaVita Inc.

NYSE:DVA

Intrinsic Alpha fair value

Locked

Current Price

$161.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.